Clinical trial
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
NCT05686408
Study timeline
Study start (actual)2023-03-02Date precision: day
Registry last updated2025-02-17
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Depressionunresolved
Depressive Disorderunresolved
Depressive Symptomsunresolved
Depressive Disorder, Majorunresolved
Depressive Episodeunresolved
Depression Severeunresolved
Interventions
TNX-601 ERDRUG
PlaceboDRUG
Sponsors & collaborators
Tonix Pharmaceuticals, Inc.lead sponsor
Rho, Inc.collaborator
Mapped research locations
ChicagoIllinois, United States1DallasTexas, United States1AtlantaGeorgia, United States1San DiegoCalifornia, United States1PortlandOregon, United States1JacksonvilleFlorida, United States1OrlandoFlorida, United States1DenverColorado, United States1AustinTexas, United States1MemphisTennessee, United States1Little RockArkansas, United States1OrangeCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05686408 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.